The need to develop a local antirestenotic mechanism to prevent in-stent thrombosis has driven the development of new generation stents. The Resolute Integrity ® stent is a zotarolimus-eluting system with a new BioLinx™ polymer that allows a slower drug elution.
Introduction
Angioplasty with stenting is recommended for patients who have a blockage in one or two coronary arteries. In the past, restenosis was the Achilles' heel for balloon angioplasty with bare metal stents, secondary to intimal hyperplasia and elastic recoil of the coronary artery.
The need to develop a local antirestenotic mechanism was raised after several unsuccessful trials of systemic antirestenosis therapies were tested in patients. 1, 2 The concept of a metallic stent covered with an antiproliferative drug started with the first generation, including sirolimus-eluting (CYPHER ® ; Cordis Corporation, Hialeah, FL, USA) and paclitaxel-eluting (Taxus™ Express 2 ™; Boston Scientific, Natick, MA, USA) stents. Drug-eluting stent(s) (DES) have significantly reduced the rates of clinical and angiographic restenosis compared with bare-metal stents (BMS), in patients undergoing percutaneous coronary interventions for symptomatic coronary artery disease. [3] [4] [5] A concern with these first-generation stents has been the risk of late thrombosis, especially after discontinuation of dual antiplatelet therapy. 6 This problem may have been related to the permanent polymers coating the stent, that were used to help in the process of drug release; these polymers may also cause inflammation and hypersensitivity reactions, which can precipitate thrombosis. 7 About 5% of DES patients require repeat procedures within a year, posing increasing risk among diabetic patients. The long-term safety of DES remains an important area of clinical investigation, particularly the avoidance of late stent thrombosis (ST). 8 Second-generation DES include the zotarolimus-eluting stent (ZES) (Endeavor ® A newer stent was recently released by Medtronic, with the name Resolute Integrity ® zotarolimus-eluting coronary stent system (R-ZES). The R-ZES is a device/drug combination product, comprised of the following device components: the Integrity coronary stent and MicroTrac delivery systems and a formulation of zotarolimus in a polymer coating. 10 In this review, we summarize the available basic and clinical evidence for this device.
Design and pharmacology of R-ZES and preclinical data Platform
The R-ZES consists of a balloon-expandable intracoronary DES pre-mounted on the MicroTrac Over the Wire or rapid exchange stent delivery system. The stent is manufactured from a cobalt alloy and is formed from a single wire bent into a continuous sinusoid pattern and then laser fused back into it. 11 
Zotarolimus
Zotarolimus is a tetrazole-containing macrocyclic immunosuppressant. It is a semisynthetic derivative of rapamycin, and an analog of sirolimus (used in the firstgeneration DES); it, however, has a shorter in vivo half-life and a reduced potential for causing systemic immunosuppression. 12 The molecular formula of zotarolimus is C52H79N5012, and its molecular weight is 966.2 Da.
The R-ZES contains 10 mcg of zotarolimus per millimeter of stent length, for all diameters, meaning that the total drug per stent is a function of stent length, irrespective of stent diameter.
The polymer system
BioLinx™ (Medtronic, Minneapolis, MN, USA) is a blend of three different polymers, ie, a hydrophobic C10 polymer, to control drug release; a biocompatible and hydrophilic C19 polymer; and polyvinyl pyrolidone, to allow an early burst of drug release. 13 The BioLinx polymer provides increased coating durability, improved biocompatibility, and extended drug elution, such that at least 85% of the zotarolimus is released within 60 days, with the remainder being released within 180 days. 14 
Preclinical data
The R-ZES has a cobalt-chromium stent backbone, BioLinx polymer, and the antirestenotic drug zotarolimus. The main difference between the R-ZES and its predecessor, the E-ZES, lies in this polymer, which has better drug-release kinetics. The E-ZES elutes the zotarolimus in 1 week, whereas the R-ZES takes 60 days to elute 85% of the zotarolimus and 180 days to elute it completely.
Therefore, one of the advantages of the BioLinx polymer is better control of the rate of drug elution, despite using a similar dose of zotarolimus to the E-ZES. Another advantage is its hydrophilic surface, which allows no adherence to activated monocytes, further supporting the noninflammatory nature of the tripolymer blend. 15, 16 A study on inflammatory scores in swine showed equivalent biocompatibility between R-ZES compared with E-ZES. 17 Scanning electron microscope studies show endothelialization as early as 28 days and confluent endothelialization at 180 days after implantation. 18 The R-ZES was found to be superior to the E-ZES and comparable with other limus-eluting stents in terms of antirestenotic efficacy.
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Clinical efficacy studies on the R-ZES
The safety and effectiveness of the R-ZES was established in the global RESOLUTE clinical trial program, which consisted of five clinical trials: RESOLUTE United States (US), RESOLUTE All-Comers, RESOLUTE International, RESOLUTE First in Man (FIM), and RESOLUTE Japan. The same product was used in all five trials -the R-ZES on rapid exchange sprint delivery system. Other independent trials have been completed in the past few months and have contributed more data to evaluate the efficacy and safety of this device. Detailed descriptions of each study can be found in Table 1 .
RESOLUTE FIM
The RESOLUTE FIM trial 13 was a prospective, nonrandomized, multicenter study of the R-ZES in 139 patients with de novo coronary lesions and with reference vessel diameters $ 2.5 and #3.5 mm and lesion length $ 14 and #27 mm. The primary end point was 9-month in-stent late lumen loss by quantitative coronary angiography. Secondary end points included major adverse cardiac events (MACE) at 30 days, and 6, 9, and 12 months; acute procedure success; and 9-month target vessel failure (TVF), target lesion revascularization (TLR), ST, neointimal hyperplastic (NIH) volume, and percent NIH volume obstruction. The 9-month in-stent late lumen loss was 0.22 ± 0.27 mm. Cumulative MACE were 4.3%, 4.3%, 7.2%, and 8.7% at 30 days, and 6, 9, and 12 months, respectively. Acute lesion, procedure, and device success rates were 100.0%, 95.7%, and 99.3%, respectively. At 9 months, TLR was 0.0%, TVF was 6.5%, ST was 0.0%, NIH volume was 6.55 ± 7.83 mm 3 , and percent NIH volume obstruction was 3.73% ± 4.05%. Overall, in this feasibility study, the Resolute stent demonstrated low in-stent late lumen loss, minimal NIH in-growth, low TLR, no ST, and acceptable TVF and MACE.
RESOLUTE US
The RESOLUTE US trial 8 recruited patients with de novo native coronary lesions suitable for one-or two-vessel treatment with stents from 2.25 to 4.0 mm in diameter. In the main analysis cohort (2.5 to 3.5 mm stents and single-lesion treatment), the primary end point was 12-month target lesion failure (TLF), defined as the composite of cardiac death, myocardial infarction, and clinically driven TLR, compared with data from E-ZES trials, adjusting for baseline covariates through propensity scores. There were 1402 patients enrolled, with a mean reference vessel diameter of 2.59 ± 0.47 mm and diabetes prevalence of 34.4%. In the main analysis cohort, TLF was 3.7% at 12 months compared with historical E-ZES results (where TLF was 6.5%). The R-ZES met the 3.3% margin of noninferiority (rate difference = −2.8%, upper one-sided 95% confidence interval [CI]: −1.3%, P , 0.001). The overall TLF rate was 4.7%, and rates of cardiac death, myocardial infarction, and TLR were 0.7%, 1.4%, and 2.8%, respectively. The 12-month rate of ST was 0.1%. In this study, the R-ZES achieved a very low rate of clinical restenosis while maintaining low rates of important clinical safety events, such as death, myocardial infarction, and ST, at 1-year follow-up.
RESOLUTE International Registry
The primary objective of the Resolute International Registry 20 was to document the safety and overall clinical performance of the R-ZES in a "real-world" patient population of 2349 patients requiring stent implantation. The primary end point was the adjudicated cumulative 1-year incidence of cardiac death and target vessel myocardial infarction. The investigators recruited 2349 patients with 3147 lesions (1.6 ± 1.0 stents per patient); among the study patients, 46.0% had acute coronary syndrome, 30.5% were diabetic, and $1 complex criterion for stent placement was present in 67.5% of patients. One-year follow-up was completed for 97.9% of patients. The 1-year incidence of the primary end point was 4.3% (95% CI: 3.5% to 5.2%) and for Academic Research Consortium definite and probable ST, 21 0.9% (95% CI: 0.5% to 1.3%). Clinically driven TLR and TLF were 3.4% (95% CI: 2.7% to 4.3%) and 7.0% (95% CI: 6.0% to 8.2%), respectively. In everyday practice, the R-ZES performed similarly well as in the Resolute All-Comers randomized trial.
RESOLUTE All-Comers
In the RESOLUTE All-Comers trial, 22 patients with at least one coronary lesion 2.25-4.0 mm in diameter, with greater than 50% stenosis, were randomly assigned to a R-ZES or a Xience V everolimus-eluting stent (XV-EES) at 17 centers in Europe and Israel. Randomization was completed by an interactive voice response system, and stratified by center. Study investigators were not masked to treatment allocation but those who did data management and analysis, and patients were masked. There were no restrictions as to the number of vessels or lesions treated, or the number of stents implanted. We assessed per specific safety and efficacy outcomes at 2 years, with specific focus on patient-related composite outcomes (all death, all myocardial infarction, and all revascularization) and stent-related composite outcomes. Analyses were by intention to treat. In total, 1140 patients were assigned to the zotarolimus-eluting stent and 1152 to the everolimus-eluting stent; of these, 1121 and 1128 patients, respectively, completed 2-year follow-up. difference 0.5%, 95% CI: −2.1 to 3.1; P = 0.736) did not differ between groups, although the rates of the stent-related outcome were substantially lower than were those for the patient-related outcome. Three patients in each group (0.3%) had very late (after 1 year) ST. 23 Overall, similar safety and efficacy outcomes were sustained between the two newgeneration DES at 2-year follow-up.
RESOLUTE Japan
The objective of the RESOLUTE Japan study 24 was to verify the safety and efficacy of the R-ZES for the treatment of de novo lesions in native coronary arteries, in 100 subjects. The primary outcome measures were in-stent late lumen loss (time frame: postprocedure and 8 months) and the difference between the postprocedure immediate minimal lumen diameter and follow-up angiography minimal lumen diameter. The results were that the R-ZES in-stent late lumen loss at 8 months was 0.13 ± 0.22 mm, which met the primary noninferiority end point (and demonstrated superiority) compared with the historical Taxus stent 8-month in-stent late lumen loss of 0.42 ± 0.50 mm.
The TwENTE trial
The aim of the TWENTE study 25 was to compare the safety and efficacy of the R-ZES with the XV-EES at 1-year follow-up. This investigator-initiated, patient-blinded, randomized noninferiority study had limited exclusion criteria (acute ST-segment elevation myocardial infarctions not eligible). Patients (n = 1391, 81.4% of the eligible population) were randomly assigned to the R-ZES (n = 697) or the XV-EES (n = 694). Liberal use of stent postdilation was encouraged.
Cardiac biomarkers were systematically assessed. respectively (absolute risk difference 0.1%; 95% CI: −2.8% to 3.0%, noninferiority = 0.001). There was no significant between-group difference in TVF components. The definiteor-probable ST rates were relatively low and similar for the R-ZES and XV-EES (0.9% and 1.2%, respectively, P = 0.59).
Definite ST rates were also low (0.58% and 0%, respectively, P = 0.12). With the XV-EES, probable ST beyond day 8 was observed only in patients not adhering to dual antiplatelet therapy. In this study, the R-ZES was noninferior to the XV-EES in treating real-world patients with a vast majority of complex lesions and off-label indications for DES, which were implanted with liberal use of postdilation.
The Optical Coherence Tomography in Long Lesions (LongOCT) trial
In the LongOCT study, 26 the vascular response to R-ZES, the ZES with prolonged drug release, was evaluated in vivo and compared with E-ZES, a ZES with faster kinetics, by means of OCT. The study had a pool of 43 patients, of which 21 were treated with "slow-release" ZES and 22 patients were treated with "fast-release" ZES. The primary end point was assessed after 6 months by the presence of in-stent NIH. The percentage of uncovered and malapposed struts were considered co-primary end points. The new generation slowrelease ZES had better suppression of the neointimal response but had a higher proportion malapposed and uncovered struts, as assessed by OCT at 6-month follow-up.
Percutaneous treatment of long native coronary lesions with drug-eluting stent-Iv (LONG-DES Iv) trial
This randomized, multicenter, prospective trial, called the LONG-DES IV, 27 compared R-ZES and sirolimus-eluting stents (SES) in 500 patients with long ($25 mm) native coronary lesions. The primary end point of the trial was in-segment late luminal loss at 9-month angiographic follow-up. The baseline characteristics were not different between the R-ZES and SES groups, including lesion lengths (32.4 ± 13.5 mm vs 31.0 ± 13.5 mm, P = 0.27). At 9-month angiographic follow-up, the R-ZES was noninferior to the SES with respect to in-segment late luminal loss, the primary study end point (0.14 ± 0.38 mm vs 0.12 ± 0.43 mm, P for noninferiority = 0.03, P for superiority = 0.68). In addition, in-stent late luminal loss (0.26 ± 0.36 mm vs 0.24 ± 0.42 mm, respectively; P = 0.78) and the rates of in-segment (5.2% vs 7.2%, respectively; P = 0.44) and in-stent (4.0% vs 6.0%, respectively; P = 0.41) binary restenosis were not significantly different between the two groups. There were no significant between-group differences in the rate of adverse clinical events (death, myocardial infarction, ST, TLR, and composite outcomes). Overall, in patients with de novo long coronary artery disease, R-ZES implantation showed noninferior angiographic outcomes as compared with SES implantation.
Talarico et al
Talarico et al (Rome, Italy) 28 conducted an independent study that compared the clinical outcome of patients treated with E-ZES and R-ZES in a total of 467 patients; of these, 233 were treated with E-ZES and 234 with R-ZES. At 12-month follow-up, MACE rate was significantly lower in the R-ZES group compared with E-ZES group (4.2% vs 14.6%; P , 0.01) and, this difference was secondary to nonsignificant lower MI and death rates, as well as significant lower TLR (3.4% vs 10.3%, P , 0.01).
Resolute Italian study in all comers
The Resolute Italian study 29 was a prospective trial conducted independently of any commercial funding (and was not part of the RESOLUTE clinical trials funded by Medtronics). The study was conducted to assess the clinical performance of R-ZES. The study patients comprised 820 high-risk patients, including patients with acute coronary syndrome (57%), diabetes mellitus (23%), and American College of Cardiology (ACC)/American Heart Association (AHA) type B2/C lesion 30 (74%). The primary end points were TLF (defined as myocardial infarction, cardiac death, or TLR) and ST as defined by the Academic Research Consortium, 21 evaluated immediately postprocedure and at 12-month follow-up. The overall in-hospital TLF was 4.0% (95% CI: 2.9%-5.6%) and comprised 0.9% (95% CI: 0.4%-1.8%) cardiac death, and 3.3% (95% CI: 2.3%-4.7%) periprocedural myocardial infarction -only two cases (0.2%, 95% CI: 0.1%-0.9%) of definite acute ST were observed during the hospital stay. At a median time of 12 months follow-up (interquartile range 10-18), the overall TLF rate was 7.1% (95% CI: 5.5%-9.0%), clinically detected revascularization was 4%, and ST (definite or probable) was 1.1%. As a conclusion, the use of E-ZES was safe, effective, and associated with favorable procedural and 12-month outcomes despite the treatment of unselected complex clinical and anatomical presentation.
Upcoming trials
At this point, some of the studies in the global RESOLUTE clinical trial program are still active: RESOLUTE US, 8 RESOLUTE International, 20 and RESOLUTE All-Comers. 22 RESOLUTE Japan's preliminary results were shown at the Japanese Association of Cardiovascular Intervention's 2011 annual meeting, 24 but formal publication of results is still pending. The RESOLUTE US trial is not only active but is still enrolling patients for a 38 mm stent-length substudy. 8 Other active studies, which will continue to accrue follow-up results in the next few years, are the TWENTE 25 trial and the LONG-DES IV trial. 27 Several other independent trials are summarized in In the following years we will see the R-ZES being tested against other DES, 31,32 such as the Taxus ® Liberté ® stent (Boston Scientific), 33 the Promus™ Element (Boston Scientif ic), 10 the Synergy™ (Boston Scientif ic), the Orsiro™ (Biotronik SE & Co, KG, Berlin, Germany), 34 the Taxus Element™ (Boston Scientific), and Xience Prime™ (Abbott Laboratories), 25 and against non-stent devices such as the IN.PACT Falcon drug-eluting balloon (Invatec Roncadelle, Italy). 35 It will be interesting to see the outcomes in more specific subtypes of lesions and patients. For example, in the Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries (RJ-SVS) trial, 36 the R-ZES's safety and efficacy will be tested in small vessels (2.25 mm). Other special populations, such as patients with long and complex lesions, will be studied in the RESOLUTE Asia trial.
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Clinical safety of the R-ZES
The United States Food and Drug Administration (FDA) approved the use of the R-ZES on February 17, 2012. The approved use has been limited so far to patients with coronary artery disease and diabetes, and is approved with a target length of #27 mm, and with reference vessel diameters of $2.25 mm to #4.2 mm.
The characteristics of the patients involved in the reviewed studies were homogeneous among the trials, and the conclusions are based on a total studied population of 7152 people ( Table 3 ). The addition of more complex coronary lesions and patients was seen in results of the RESOLUTE US, 8 RESOLUTE All-Comers, 22 TWENTE, 25 and RESOLUTE Italian 29 trials. Among these complex patient populations were patients with acute coronary syndromes, multiple lesions, multivessel disease, and, in some, the presence of at least one off-label criterion, meaning renal insufficiency, ejection fraction of less than 30%, the occurrence of an acute myocardial infarction within the previous 72 hours, more than one lesion per vessel, lesions of more than 27 mm, bifurcations, bypass grafts, unprotected left main artery, lesions with thrombus, or total occlusions. Smaller lesions (,2.25 mm) were rarely intervened in any of these trials ( Table 4) .
The clinical safety profile of the R-ZES suggests that its antirestenotic efficacy is superior to that of the E-ZES and similar to other limus-eluting stents. 19 Primary and secondary end point results are shown in Table 5 for the RESOLUTE trials; similar data for all other studies on R-ZES are also presented in Table 6 .
The RESOLUTE FIM trial 13 was the first to report the safety and efficacy of this stent. The safety was comparable to the E-ZES; 8 RESOLUTE FIM also showed promising efficacy, with significantly less in-stent late lumen loss at nine months: 0.22 ± 0.27 mm, which was significantly less than seen in the ENDEAVOR II study. 38 It also demonstrated that there was no overt positive remodeling of the vessels and little or no recoil of the stent. Also, the presence of low NIH volume and percent NIH volume obstruction was consistent with the antiproliferative effect of zotarolimus. Six cases of late incomplete apposition were noted at 9-month follow-up with intravascular ultrasound, but only one required a TLR at 280 days. Guagliumi et al 26 have also described the presence of a higher rate of late incomplete apposition with R-ZES stents, through the use of OCT. Late incomplete apposition is a phenomenon potentially associated with late ST, but this has not been conclusively demonstrated.
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Lesion length and complexity
Along with angiography and intravascular ultrasound, OCT has been used in vivo to evaluate the vascular response to stents, and, according to Guagliumi et al, 26 the differences found between the R-ZES and E-ZES were based on different release kinetics, with the R-ZES showing slow release and the E-ZES a fast-release kinetic. The OCT showed more suppression of NIH with the R-ZES arm versus the E-ZES but a higher proportion of patients with uncovered and malapposed struts at 6-month follow-up. It has been demonstrated in the past that overlapping sites of DES have greater NIH compared with non-overlapping segments. 26 Interestingly, the degree of NIH response in the R-ZES group was similar between overlapping and nonoverlapping segments, allowing interventionists to treat longer and more complex lesions.
Lesion complexity is another factor that was described in some studies, 8, 20, 22, 23, 25 including the one by Talarico et al 28 that described that patients treated with the R-ZES had longer and more complex lesions, with higher rate of ACC/AHA B2/C, 30 and higher SYNTAX™ score 40, 41 and bifurcated lesions. The outcome in bifurcation lesions was evaluated in the multicenter Italian registry that evaluated lesions with more than 70% stenosis at a major bifurcation point and a main vessel diameter of more than 2.5 mm. Here, 180 patients were enrolled and showed a procedural success rate of 98.3% and no reported MACE or ST in the first 9 months. 34 
Small vessel disease
During the 2012 meeting of the ACC, 42 the RESOLUTE group presented updated data on the safety and effectiveness Prior CABG (%) of the R-ZES on vessels of #2. The data from all five RESOLUTE studies were adjusted for differences in patients' baseline characteristics, and the RESOLUTE group concluded that, after 2 years of follow-up, there were no significant differences in the safety and effectiveness outcomes between patients with large-and small-vessel disease. Interestingly, patients with small-vessel disease were older and had a higher proportion of females and a high rate of diabetes, hypertension, hyperlipidemia, and multivessel disease. 
Off-label use/complex patients
Some of the reviewed trials have expanded patient eligibility to include more complex patients and lesions, 8, 22, 25 with the idea of expanding the treatment options for these patients. It is known that diabetes, recent myocardial infarction, chronic kidney disease, ostial lesions, and total occlusions represent a higher risk for restenosis and ST. The results demonstrated higher event rates in complex versus noncomplex patients but no differences between the R-ZES and other DES currently being used in clinical practice. Overall, there is encouraging safety data in higher-risk populations.
Diabetic patients
A total of 2024 diabetic patients, including insulin-and noninsulin-dependent diabetics, participated in all the ten studies reviewed by us, representing 28.3% of the sample. As we already know, diabetes is a factor for poor prognosis in patients with coronary disease as well as for higher rate of periprocedural complications, such as in-stent stenosis, ST, and death. 43 The rate of TLF in this group after 1 year was similar to that of the overall trial population, which demonstrates efficacy and safety in this particular group of patients. 
In-stent thrombosis
The data on ST seems to be conflicting at this point. In the RESOLUTE All-Comers trial, the rate of definite ST was significantly higher in the R-ZES group (1.2%) than in the XV-EES group (0.3%, P = 0.01) at 12 months, which was primarily related to a higher rate of definite ST at 30 days in the zotarolimus-stent group than in the everolimus-stent group. 23 Talarico et al, 28 reported a significantly higher number of definite, probable, and possible cases of ST in the E-ZES group (with one case of definite ST), while no definite or probable 
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ST was detected in the R-ZES group. The TWENTE trial 25 showed a lower incidence of definite in-stent thrombosis than was seen in the RESOLUTE All-Comers trial.
Patient-focused perspective
One of the most fearsome complications for a DES is in-stent thrombosis, which is often due to improper stent implantation. 6 Dual antiplatelet agents are indicated for at least 12 months in order to prevent this risk. For this reason, patients that are candidates for DES should be screened for contraindications to prolonged antiplatelet therapy. In all of the studies reviewed, a loading dose of clopidogrel 300 mg was given to the patients within 24 hours before the procedure, then 75 mg daily for at least 6 months to 1 year. Aspirin was used to complete the dual antiplatelet therapy, at a dose ranging from 75 to 100 mg daily indefinitely, unless the patient had indication for anticoagulation, in which case it was continued for at least 1 month after the procedure without changes in the dose or duration of clopidogrel. Procedural anticoagulation was achieved with heparin, maintaining an activated clotting time . 250 seconds, or between 200 and 250 seconds if a glycoprotein IIb/IIIa receptor inhibitor was administered. The use of glycoprotein IIb/IIIa receptor inhibitors was left to operator's discretion.
The studies on R-ZES, have suggested a variety of possible advantages in special population, such as diabetic patients, 8, 24 and patients with more complex coronary lesions, such as multivessel disease, small-vessel disease, long lesions, bifurcations, or trifurcations. 8, 13, 23, 24 Technically, this new technology may offer superior scaffolding and a reduced profile exchange joint, without compromising on radial strength. The R-ZES has excellent radial strength and measures 1146 mmHg radial pressuresuperior to the Promus Element and XV-EES, which measure 1000 mmHg and 850 mmHg radial pressure, respectively. The R-ZES also offers greater pushability, requiring a push force of 20 g/f, for more accurate delivery to the lesion site compared with the XV-EES, which requires an average push force of 86 g/f.
The dosage and duration of dual antiplatelet therapy remains as per guidelines 44 and should be continued for a year, and there is not enough data at this point to support any changes. Long-term studies are indicated to prospectively assess whether a shorter duration of dual antiplatelet therapy is safe and effective.
Conclusion and future perspectives
The R-ZES has shown promising results and introduced a new possible mechanism to prevent ST with its addition of the new polymer coating and delivery system. It also uses one continuous sinusoidal metallic strand to enhance range of motion, which may result in an easier and safer delivery, Table 6 Global data on safety and effectiveness in other R-ZES studies (12- and add to the technical advantage for the Interventionist by reducing the profile and improved pushability. The data on clinical efficacy is promising and the safety, so far, is acceptable (at the same level as other widely used DES). Longer-term follow-up will further bolster knowledge about efficacy and safety issues.
As the use of the device extends across the US and the world, we need to continue to monitor the real-world use and results, to determine whether these results will remain generalizable to longer-term follow-up beyond 2 years and specifically, to higher risk subgroups. There is no doubt that this stent will have a major role in the treatment of coronary artery disease in the near future. Of note, the R-ZES is the first DES approved by the FDA for use in patients with diabetes, who account for about 30% of the nearly one million percutaneous cardiac interventions performed in the US each year. Overall, the R-ZES offers several notable benefits, including outstanding deliverability, which means it's easy to deliver to the stenosis site, and efficacy in complex patients and diabetics, but additional longer term safety and efficacy data are needed to cement its place in the DES armamentarium.
